# Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

> **NCT05655013** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Aarhus University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Zoledronate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05655013
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05655013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05655013, "Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05655013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*